Ibogaine's Patents Are Split Between a 1980s Heroin Cure and a Company Now Ahead in the Clinic

A company-by-company look at who holds ibogaine's 53 patents — and the rare case in this series where the biggest patent holder is also the one furthest along toward an actual FDA approval.

Ibogaine sits mid-table in our patent tracker: 15 granted, 38 pending, ahead of LSD and MDMA, behind DMT, 5-MeO-DMT, psilocybin, and ketamine. We've now covered psilocybin, 5-MeO-DMT, LSD, and ketamine from the same TREA pull. Ibogaine is the odd one out structurally, too: its foundational patents are almost exactly as old as the war on drugs, and — unlike every other compound in this series — its largest patent holder is also its clinical front-runner, not a company sitting on IP while someone else does the trial work.

Who's Actually Filing

Company	Compounds Covered	Granted	Pending	Est. Expiration
CaaMTech, LLC	Psilocybin, DMT, 5-MeO-DMT, Ibogaine	7	18	2038–2043
DemeRx, Inc.	Ibogaine	5	20	2031–2037
Atai Therapeutics, Inc.	Psilocybin, Ibogaine, DMT, 5-MeO-DMT	3	6	2042–2043
University of Minnesota	Ketamine, Ibogaine	2	1	2015–2038 (one already expired)
NDA International, Inc.	Ibogaine	2	0	2008–2010 (both expired)

The Original Patents Belong to the Man Who Discovered the Effect

Howard Lotsof, an American addict-turned-researcher, noticed ibogaine's anti-addictive effect on himself in 1962 after taking it recreationally and finding his heroin withdrawal simply stopped. Twenty years later he patented it: US 4,499,096 in 1985, "Rapid Method for Interrupting the Narcotic Addiction Syndrome," followed by a series of additional patents through 1992 covering cocaine, amphetamine, alcohol, nicotine, and poly-drug dependency specifically. NDA International, the entity now holding what's left of that portfolio, shows 2 granted patents in our data — both already expired, in 2008 and 2010. Lotsof's original composition-of-matter claims on using ibogaine for addiction have been open prior art for over a decade. Anyone filing today, including the two largest holders below, is patenting something narrower: a specific metabolite, formulation, or treatment protocol layered on top of a discovery whose original patents ran out before most of today's companies existed.

DemeRx: The Rare Case Where the Biggest Holder Is Also the Leader

DemeRx, Inc., a private company, holds the most ibogaine-specific IP in our dataset — 5 granted, 20 pending, none carrying terminal disclaimers. In April 2026, the FDA accepted DemeRx's Investigational New Drug application for DMX-1001, an oral formulation of noribogaine (ibogaine's primary active metabolite) for alcohol use disorder — the first time the agency has authorized a US clinical trial of any ibogaine-class compound. The company has since completed a multiple-ascending-dose safety trial in healthy volunteers and is targeting a Phase 2 trial in AUD patients for 2027. Noribogaine stays in the body far longer than ibogaine itself, which is the pitch: sustained neuroplastic effects without redosing the parent compound's more acute cardiac risk profile.

This breaks the pattern from every other piece in this series. With psilocybin, the biggest clinical bet (Compass) and biggest patent holder are the same company, but a nonprofit (Usona) is deliberately patent-free. With 5-MeO-DMT and LSD, the clinical leaders (GH Research, Definium) hold almost no patents at all. With ibogaine, DemeRx is both — the company furthest along in an actual FDA process is also sitting on the largest ibogaine-specific patent position of anyone we track.

The Rest of the Field

CaaMTech, the private Issaquah, WA prodrug chemistry company covered in our psilocybin piece, holds more combined patents than DemeRx (7 granted, 18 pending) but spread across four compounds — the same salts-and-prodrugs strategy it applies everywhere, not an ibogaine-specific program.

Atai Therapeutics, Inc. (Nasdaq: ATAI via parent AtaiBeckley) holds 3 granted and 6 pending, distinct from its parent entity's own separate filings (1 grant, 14 applications). AtaiBeckley has agreed to be acquired by Eli Lilly, expected to close by late 2026 — but that deal is built around BPL-003, AtaiBeckley's 5-MeO-DMT program, not ibogaine, which looks more like a side bet in the portfolio than the acquisition's rationale.

University of Minnesota rounds out the academic side: 2 granted (one already expired), 1 pending, spanning both ketamine and ibogaine research.

Where the Public Money Is Going

None of the current state-level ibogaine pushes show up in this patent data, because none of them are patent plays — they're funding mechanisms aimed at generating the clinical data DemeRx and everyone else will eventually need. Texas committed $50 million via its Ibogaine Initiative in 2025, though implementation has reportedly lagged the statute's requirements. Michigan's HB 6020 proposes joining a six-state consortium that would pool trial data toward one consolidated FDA submission. Separately, Stanford's MISTIC program has already published results from 30 Special Operations veterans treated with magnesium-ibogaine for traumatic brain injury, with no serious cardiac events reported. None of this generates new IP by itself, but it's the clinical evidence base that makes IP like DemeRx's worth something down the line.

The Pattern

Every other compound in this series has split cleanly into "who owns the IP" and "who's actually closest to approval," usually as two different companies making two different bets. Ibogaine doesn't split that way, at least not yet: the patent leader and the clinical leader are the same company, betting on a metabolite rather than the parent molecule, decades after the original discoverer's own patents ran out and public money started flowing in behind it. Whether that concentration holds as Phase 2 data arrives, or whether academic and state-funded programs generate a genuine alternative pathway the way Usona did for psilocybin, is the open question for whoever writes this update in a year.

This is business and regulatory reporting, not medical advice. DMX-1001 is not FDA-approved; ibogaine itself remains Schedule I and carries documented cardiac risks requiring medical monitoring. No compound discussed here is approved for the indications mentioned.